Skip to main content

Funny Feller

It's a bit early for April Fool's Day, but University of Oxford researcher Stephan Feller apparently couldn't wait to do a little gentle tweaking of the 'omics community with a "paper" published this week in the journal Cell Communication & Signaling (of which he happens to be the editor-in-chief.)

In it, he introduces a new concept that he says is on the cusp of taking the scientific community by storm — microproteins, or, because everyone loves a good abbreviation, miPs. What are they? Nobody knows. That shouldn't stop them, though, from becoming the next big thing, Feller says.

"To study them is easy," he writes. "Just mass spec your protein dye fronts to death, synthesise all found miP candidates, biotinylate them, and go fishing for binding partners."

These heretofore non-existent molecules "can be expected to steer embryonic development and stem cell differentiation, to play a role in cancers and neurodegenerative diseases and should also make great leads for future drugs," Feller says. "Clearly, miPs are yet another Nobel Prize lurking, and begging for attention."

Sounds like someone has read one too many overhyped journal submissions.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.